Insider Richard Heyman plans 1,230-share sale in Enliven Therapeutics (NASDAQ: ELVN)

Rhea-AI Filing Summary

Enliven Therapeutics investor plans to sell 1,230 common shares. The planned sale is to be executed through Jefferies LLC on Nasdaq, with an approximate sale date of 01/20/2026 and an aggregate market value of $32,853.30 for this block. The filing notes that 59,000,000 shares of the issuer’s stock were outstanding.

The seller acquired these 1,230 shares as founder shares from Enliven Therapeutics on 01/25/2020. Over the past three months, Richard Heyman has sold additional Enliven securities in two transactions: 8,015 shares on 01/08/2026 for gross proceeds of $200,655.12 and 4,285 shares on 01/09/2026 for gross proceeds of $107,125.60. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Enliven’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	1230	32853.30	59000000	01/20/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2020	Founders Shares	Enliven Therapeutics			1230	01/25/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Heyman 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/08/2026	8015	200655.12
Richard Heyman 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/09/2026	4285	107125.60

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing show for Enliven Therapeutics (ELVN)?

It shows a planned sale of 1,230 common shares of Enliven Therapeutics through Jefferies LLC on Nasdaq, with an approximate sale date of 01/20/2026 and an aggregate market value of $32,853.30 for this block.

Who is selling shares of Enliven Therapeutics (ELVN) in this Form 144?

The filing lists Richard Heyman as the person who has sold Enliven securities in recent transactions and identifies a planned sale of 1,230 common shares that were originally acquired as founder shares from Enliven Therapeutics.

How and when were the 1,230 Enliven Therapeutics (ELVN) shares acquired?

The 1,230 common shares to be sold were acquired on 01/25/2020 as founder shares from Enliven Therapeutics, with the date of payment also listed as 01/25/2020 and the nature of payment noted as N/A.

What recent sales of Enliven Therapeutics (ELVN) shares does the Form 144 disclose?

Over the past three months, Richard Heyman sold Enliven securities in two transactions: 8,015 shares on 01/08/2026 for gross proceeds of $200,655.12 and 4,285 shares on 01/09/2026 for gross proceeds of $107,125.60.

How many Enliven Therapeutics (ELVN) shares are outstanding according to this filing?

The Form 144 states that there are 59,000,000 common shares of Enliven Therapeutics outstanding, providing a baseline for the size of the planned 1,230-share sale.

What representation does the seller make in this Enliven Therapeutics (ELVN) Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Enliven’s current or prospective operations that has not been publicly disclosed.